Development of plumbagin-loaded phospholipid-Tween® 80 mixed micelles: Formulation, optimization, effect on breast cancer cells and human blood/serum compatibility testing

Therapeutic Delivery

Volumn 4, Issue 10, 2013, Pages 1247-1259

  Bothiraja, Chellampillai ^a   Kapare, Harshad S ^a   Pawar, Atmaram P ^a   Shaikh, Karimunnisa S ^b  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b UNIVERSITY OF PUNE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885599859     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.92     Document Type: Article

References (50)

1. Bothiraja C, Pawar AP, Shaikh KS et al. Eudragit® EPO based nanoparticle suspension of andrographolide: in vitro and in vivo. Nanosci. Nanotech. Lett. 1(3), 156-164 (2009).
2. Bothiraja C, Pawar AP. Andrographolide, a novel bioactive phytoconstituent encapsulated in sustained release biodegradable nanoparticles. Int. J. Nanotechnol. 8(8-9), 764-778 (2011).
3. Schutz CA, Jeanneret LJ, Mueller H et al. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond.) 8(3), 449-467 (2013).
4. Sun M, Su X, Ding B et al. Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine (Lond.) 7(7), 1085- 1100 (2012).
5. Deepagan VG, Sarmento B, Menon D et al. In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles. Nanomedicine (Lond.) 7(4), 507-519 (2012).
6. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3(10), 768-780 (2003).
7. Gupta SG, Kim JH, Prasad S et al. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 29(3), 405-434 (2010).
8. Bothiraja C, Joshi PP, Dama GY et al. Rapid method for isolation of plumbagin, an alternative medicine from roots of Plumbago zeylanica. Eur. J. Integr. Med. 3(3), 39-42 (2011).
9. Bothiraja C, Pawar AP, Dama GY et al. Novel solvent-free Gelucire extract of Plumbago zeylanica using non-everted rat intestinal sac method for improved therapeutic efficacy of plumbagin. J. Pharmacol. Toxicol. Methods 66(1), 35-42 (2012).
10. Kawiak J, Piosik G, Stasilojc A et al. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol. Appl. Pharmacol. 223(3), 267-276 (2007).
11. Bothiraja C, Pawar AP, Mali AJ et al. Improved pharmaceutical properties of surface modified plumbagin bioactive crystals. Int. J. Surf. Sci. Eng. 7(2), 181-195 (2013).
12. Kumar MR, Aithal BK, Udupa N et al. Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma. Drug Deliv. 18(7), 511-522 (2011).
13. Mandala Rayabandla SK, Aithal K, Anandam A et al. Preparation, in vitro characterization, pharmacokinetic and pharmacodynamic evaluation of chitosan-based plumbagin microspheres in mice bearing B16F1 melanoma. Drug. Deliv. 17(3), 103-113 (2010).
14. Srinivas P, Patra CR, Bhattacharya S et al. Cytotoxicity of naphthoquinones and their capacity to generate reactive oxygen species is quenched when conjugated with gold nanoparticles. Int. J. Nanomedicine 6(9), 2113-2122 (2011).
15. Chen ZF, Tan MX, Liu YC et al. Synthesis, characterization and preliminary cytotoxicity evaluation of five lanthanide (III)-plumbagin complexes. J. Inorg. Biochem. 105(3), 308-316 (2011).
16. Kulthe SS, Inamdara NN, Choudharia YM et al. Mixed micelle formation with hydrophobic and hydrophilic Pluronic block copolymers: implications for controlled and targeted drug delivery. Colloid Surf. B Biointerfaces 88(2), 691-696 (2011).
17. Chiappetta DA, Hocht C, Opezzo J et al. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Lond.) 8(2), 223-237(2013).
18. Yoncheva K, Calleja P, Agueros M et al. Stabilized micelles as delivery vehicles for Paclitaxel. Int. J. Pharm. 436(1-2), 258-264 (2012).
19. Gao H, Cao S, Chen C et al. Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and antitumor effect in breast cancer. Nanomedicine (Lond.) 8(9), 1429-1442 (2013).
20. Gao ZG, Tian L, Hu J et al. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J. Control. Release 152(1), 84-89 (2011).
21. Li X, Zhang Y, Fan Y et al. Preparation and evaluation of novel mixed micelles as nanocarriers for intravenous delivery of propofol. Nanoscale. Res. Lett. 6(3), 275 (2011).
22. Tong S, Xiang B, Dong D et al. Enhanced antitumor efficacy and decreased toxicity by self-Associated docetaxel in phospholipid-based micelles. Int. J. Pharm. 434(1), 413-419 (2012).
23. Muthu MS, Kulkarni SA, Liu Y et al. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine (Lond.) 7(3), 353-364 (2012).
24. Saxena V, Hussain MD. Poloxamer 407/ TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer. Int. J. Nanomed. 7(2), 713-721 (2012).
25. Giddam AK, Zaman M, Skwarczynski M et al. Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine (Lond.) 7(12), 1877-1893 (2012).
26. Lemarie F, Chang CW, Blatchford DR et al. Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration. Nanomedicine (Lond.) 8(2), 181-192 (2013).
27. Rupp C, Steckel H, Muller BV. Mixed micelle formation with phosphatidylcholines: the influence of surfactants with different molecule structures. Int. J. Pharm. 387(1-2), 120-128 (2010).
28. Simoes SI, Tapadas JM, Marques CM et al. Permeabilisation and solubilisation of soybean phosphatidylcholine bilayer vesicles, as membrane models, by polysorbate, Tween 80. Eur. J. Pharm. Sci. 26(3-4), 307-317 (2005).
29. Nagpal K, Singh SK, Mishra ND. Optimization of brain targeted gallic acid nanoparticles for improved antianxiety-like activity. Int. J. Biol. Macromol. 57(6), 83-91 (2013).
30. Liu J, Zhao X. Design of self-Assembling peptides and their biomedical applications. Nanomedicine (Lond.) 6(9), 1621-1643 (2011).
31. Love SA, Thompson JW, Haynes CL. Development of screening assays for nanoparticle toxicity assessment in human blood: preliminary studies with charged Au
32. Meng J, Xing J, Wang Y et al. Epigenetic modulation of human breast cancer by metallofullerenol nanoparticles: in vivo treatment and in vitro analysis. Nanoscale 3(11), 4713-4729 (2011).
33. Mu CF, Balakrishnan P, Cui FD et al. The effects of mixed MPEG-PLA/Pluronic® copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 31(8), 2371-2379 (2010).
34. Mohanty C, Acharya S, Mohanty AK et al. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond.) 5(3), 433-449 (2010).
35. Kim S, Shi Y, Kim JY et al. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert. Opin. Drug Deliv. 7(1), 49-62 (2010).
36. Leonhard V, Alasino RV, Bianco ID et al. Self-Assembled micelles of monosialogangliosides as nanodelivery vehicles 2 for taxanes. J. Control. Release. 162(3), 619-627 (2012).
37. Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond.) 7(10), 1577-1590 (2012).
38. Elizondo E, Veciana J, Ventosa N. Nanostructuring molecular materials as particles and vesicles for drug delivery, using compressed and supercritical fluids. Nanomedicine (Lond.) 7(9), 1391-1408 (2012).
39. Bamrungsap S, Zhao Z, Chen T et al. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine (Lond.) 7(8), 1253-1271 (2012).
40. Liang H, Yang Q, Deng L et al. Phospholipid- Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel. Drug. Dev. Ind. Pharm. 37(5), 597-605 (2011).
41. Cohen DE, Carey MC. Acyl chain unsaturation modulates distribution of lecithin molecular species between mixed micelles and vesicles in model bile. Implications for particle structure and metastable cholesterol solubilities. J. Lipid. Res. 32(8), 1291-1302 (1992).
42. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug. Deliv. Rev. 54(5), 631-651 (2002).
43. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer. 2(2), 83-90 (2002).
44. Cohen-Sela E, Chorny M, Gutman D et al. Characterization of monocytes-Targeted nanocarriers biodistribution in leukocytes in ex vivo and in vivo models. Nano Biomed. Eng. 2(2), 91-99 (2010).
45. Lichtenberger LM, Graziani LA, Dial EJ et al. Role of surface-Active phospholipids in.gastric cytoprotection. Science 219(4590), 1327-1329 (1983).
46. Martin GP, Marriott C. Membrane damage by bile salts: the protective function of phospholipids. J. Pharm. Pharmacol. 33(12), 754-759 (1981).
47. Perrault SD, Walkey C, Jennings T et al. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9(5), 1909-1915 (2009).
48. Koo OM, Rubinstein I, Onyuksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine (Lond.) 1(1), 77-84 (2005).
49. Zhang W, Shi Y, Chen Y et al. Enhanced antitumor efficacy by paclitaxel-loaded luronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur. J. Pharm. BioPharm. 75(3), 341-353 (2010).
50. Danhier F, Lecouturier N, Vroman B et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J. Control. Release 133(1), 11-17 (2009).